Winners of 2020 BVDzero Case Awards announced

Ingelheim, Germany, May 25, 2020 – Boehringer Ingelheim has announced the winners of the 2020 BVDzero Case Awards. This biennial initiative reflects Boehringer Ingelheim’s long-term commitment to promoting health and well-being of farm animals.

“Bovine viral diarrhea virus (BVDV) is one of the most common diseases in cattle, causing negative health, economic and immunosuppressive consequences on the farms. We are committed to fight against BVDV and support our veterinarians and farmers with innovative preventative solutions,” commented Steve Williams, Head of Global Strategic Marketing Ruminants at Boehringer Ingelheim Animal Health.

This year’s BVDzero press conference and award ceremony took place virtually on May 25, 2020. The award winners have been selected by the BVDzero Committee, consisting of renowned external experts in the field of bovine health, during an online meeting.

Boehringer Ingelheim provided a total prize of 15,000 euros for the top 10 clinical cases entered. Around 30 submitted cases included submissions from the UK, Spain, the Netherlands, France, Jordan, Turkey and South Korea.

The authors of the top five winning cases had the opportunity to present their submissions during the online press conference. They accepted their prizes from Prof. Volker Moennig, Head of the BVDzero Committee.

Through the BVDzero Case Awards, Boehringer Ingelheim aims to keep encouraging the search for both clinical and subclinical cases of BVD in cattle herds. The company believes that such events will help increase BVD awareness and, as a result, help reduce its prevalence.

The top 10 clinical cases were as follows:

1.         Magdalini Sioukiouroglou (UK)

2.         Paul Crawford (UK)

3.         Laura Donovan (UK)

4.         Hans Verweij (NL)

5.         Laura-May Canonne (FR)

6.         Nikki Moore (UK)

7.         Niels Geurts (NL)

8.         Sameeh Abutarbush (JO)

9.         Rebecca Gay (UK)

10.       Anne-Cécile Thirion (FR)

Congratulations!

The Boehringer Ingelheim BVDzero team plans to continue this initiative in the future.

More information is available on http://www.bvdzero.com site.

Boehringer Ingelheim Animal Health Business Unit

Boehringer Ingelheim is the second largest animal health business in the world, with net sales of 4 billion euros in 2019 and presence in more than 150 markets.

As the lives of animals and humans are intertwined, across the globe, our 10,000 employees are dedicated to enhancing the well-being of both – through science and innovation, as well as with their commitment and passion.

Respect for animals, people and the environment is at the heart of what we do. We develop medicines, services and innovative digital technologies to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society- threatening diseases.

For more information visit: www.boehringer-ingelheim.com/animal-health/overview.

Boehringer Ingelheim

Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.

As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of 19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.

We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com.

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.